What is Beyfortus?
Beyfortus is a preventative antibody that helps protect babies against serious RSV-related lung infections.
While antibodies are naturally produced by our immune system to combat viruses, a baby's immune system may not be strong enough to generate antibodies to fight RSV.
This is where preventative antibodies play a crucial role in providing additional protection. Speak to your doctor about Beyfortus for your baby’s RSV protection.
​
Beyfortus is recommended for all babies between birth and 7 months of age, except for those whose mothers received the vaccine during pregnancy.
​
Beyfortus is administered between October 1st and March 31st of each year. ​​​
​
​
Is Beyfortus FDA approved?
Yes, Beyfortus is FDA approved to help prevent serious RSV lung infections in babies. It's also recommended by the American Academy of Pediatrics (AAP).
Beyfortus has been added to the approved immunization schedule for babies and can be given at the same time as other routine childhood vaccines.
Indications
Nirsevimab is not needed for most infants aged <8 months whose pregnant parent received RSVpreF vaccine ≥14 days before giving birth.
Nirsevimab may be considered for infants born to a vaccinated pregnant parent in rare circumstances when, based on the clinical judgment of the health care provider, the potential incremental benefit of administration is warranted. These situations include, but are not limited to:
- Infants born to pregnant people who might not have mounted an adequate immune response to vaccination (eg, persons with immunocompromising conditions) or who have conditions associated with reduced transplacental antibody transfer (eg, persons living with HIV infection);
-
Infants who might have experienced loss of transplacentally acquired antibodies, such as those who have undergone cardiopulmonary bypass or extracorporeal membrane oxygenation;
-
Infants with substantially increased risk for severe RSV disease (eg, hemodynamically significant congenital heart disease or intensive care admission requiring oxygen at hospital discharge).
Infants and children 8 through 19 months of age who are at increased risk of severe RSV disease and entering their second RSV season, including those recommended by the AAP to receive palivizumab, regardless of RSV vaccination status of the pregnant parent. This includes the following:
-
Infants and children with chronic lung disease of prematurity who required medical support (chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) at any time during the 6-month period before the start of the second RSV season.
-
Infants and children who are severely immunocompromised.
-
Infants and children with cystic fibrosis who have manifestations of severe lung disease (previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest imaging that persist when stable) or have weight-for-length that is less than the 10th percentile.
-
American Indian and Alaska Native children.